ReviewCancer immunology, immunotherapy : CII2010
Killer dendritic cells and their potential for cancer immunotherapy.
Review in Cancer immunology, immunotherapy : CII, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- Bronchoalveolar lavage microbiota signatures and stage-associated alterations in early-stage and advanced-stage non-small cell lung cancer: a pilot study.Journal of translational medicine · 2026Article
- Article
- Effective Cytotoxicity of Dendritic Cells against Established T Cell Lymphomas in Mice.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Mathematical Modeling, Analysis, and Simulation of Tumor Dynamics with Drug Interventions.Computational and mathematical methods in medicine · 2019Article
- Immunological effects of vaccines combined with granulocyte colony-stimulating factor on a murine WEHI-3 leukemia model.Oncology letters · 2017Article
- Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity.Scientific reports · 2017Article
- Exploiting the critical perioperative period to improve long-term cancer outcomes.Nature reviews. Clinical oncology · 2015Review
- Immunotherapy for lung cancer: for whom the bell tolls?Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15.European journal of immunology · 2014Article
- Tumoricidal activity of human dendritic cells.Trends in immunology · 2014Review
- Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy.Human vaccines & immunotherapeutics · 2013Review
- Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement.Brain, behavior, and immunity · 2013Review
- CD56 marks human dendritic cell subsets with cytotoxic potential.Oncoimmunology · 2013Article
- Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α -Galactosylceramide-Stimulated Natural Killer T Cells.BioMed research international · 2013Article
- Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.Critical reviews in immunology · 2013Review
- A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Review
- Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells.Oncoimmunology · 2012Article
- Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential.PloS one · 2012Article
- Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.Immunology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Known for years as the principal messengers of the immune system, dendritic cells (DC) represent a heterogeneous population of antigen presenting cells critically located at the nexus between innate and adaptive immunity. DC play a central role in the initiation of tumor-specific immune responses as they are endowed with the unique ability to take up, process and present tumor antigens to naïve CD4(+) or CD8(+) effector T lymphocytes. By virtue of the cytokines they produce, DC also regulate the type, strength and duration of T cell immune responses. In addition, they can participate in anti-tumoral NK and NKT cell activation and in the orchestration of humoral immunity. More recent studies have documented that besides their primary role in the induction and regulation of adaptive anti-tumoral immune responses, DC are also endowed with the capacity to directly kill cancer cells. This dual role of DC as killers and messengers may have important implications for tumor immunotherapy. First, the direct killing of malignant cells by DC may foster the release and thereby the immediate availability of specific tumor antigens for presentation to cytotoxic or helper T lymphocytes. Second, DC may participate in the effector phase of the immune response, potentially augmenting the diversity of the killing mechanisms leading to tumor elimination. This review focuses on this non-conventional cytotoxic function of DC as it relates to the promotion of cancer immunity and discusses the potential application of killer DC (KDC) in tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.